Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology

Patent Citations (38)

Non-Patent Literature (93)

• Jubala et al, Vet Pathol 42: 468-476, 2005.Examiner
• Zhu et al, Investigational New Drugs 17: 195-212, 1999.Examiner
• Stancovski et al, Proceedings of the National Academy of Science USA 88: 8691-8695, 1991.Examiner
• Riemer et al, Mol. Immunol. 42: 1121-1124, 2005.Examiner
• Mecchia et al., “Type I consensus interferon (CIFN) gene transfer into human melanoma cells up-regulates p53 and enhances cisplatin-induced apoptosis: implications for new therapeutic strategies with IFN-alpha”, Gene Ther. (2000) 7, 167-179.Applicant
• Newlon et al., “A Novel Mechanism of PKA Anchoring Revealed by Solution Structures of Anchoring Complexes”, EMBO J. 2001; 20:1651-1662.Applicant
• Newlon et al., “The molecular basis for protein kinase A anchoring revealed by solution NMR”, Nature Struct. Biol. 1999; 3:222-227.Applicant
• Ngo et al., “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox”, The Protein Folding Problem and Tertiary Structure Prediction, Ch. 14, pp. 492-495, (Mertz & Le Grand, Eds.), Birkhauser Boston, 1994.Applicant
• Osborn et al., “Pharmacokinetic and Pharmacodynamic Studies of a Human Serum Albumin-Interferon-α Fusion Protein in Cynomolgus Monkeys”, J. Pharmacol. Exp. Ther. 303(2):540-548 (2002).Applicant
• Oyen et al., “Human testis cDNA for the regulatory subunit Rllα of cAMP-dependent protein kinase encodes an alternate amino-terminal region”, FEBS Letters 246:57-64, 1989.Applicant
• Ozzello et al., “Conjugation of interferon alpha to a humanized monoclonal antibody (HuBrE-3vI) enhances the selective localization and antitumor effects of interferon in breast cancer xenografts”, Breast Cancer Res. Treat. 48: 135-147 (1998).Applicant
• Paquette et al., “Interferon-α and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells”, J. Leukoc. Biol. 64:358-367; 1998.Applicant
• Pelham et al., “Interferon-α conjugation to human osteogenic sarcoma monoclonal antibody 791T/36”, Cancer Immunol. Immunother. 1983;15(3):210-216.Applicant
• Pepinsky et al., “Improved Pharmacokinetic Properties of a Polyethylene Glycol-Modified Form of Interferon-β-1a with Preserved in Vitro Bioactivity”, Pharmacol. Exp. Ther. 2001; 297(3):1059-1066.Applicant
• Pilling et al., “Interferonβ mediates stromal cell rescue of T cells from apoptosis”, Eur. J. Immunol. 29:1041-1050 (1999).Applicant
• Rabjohn et al., “Molecular Cloning and Epitope Analysis of the Peanut Allergen Ara h 3”, J. Clinical Investigation 103 (4):535-542 (1999).Applicant
• Raefsky et al., “Studies of Interferon as a regulator of hematopoietic cells proliferation”, J. Immunol. 135 (4):2507-2512 (1985).Applicant
• Rose et al., “Structural basis of dimerization, coactivator recognition and MODY3 mutations in HNF-1α”, Nature Struct. Biol. 2000; 7:744-748.Applicant
• Rosendahl et al., “A Long-Acting, Highly Potent Interferon α-2 Conjugate Created Using Site-Specific PEGylation”, Bioconjugate Chem. 2005;16:200-207.Applicant
• Rossi et al., “Novel Designs of Multivalent Anti-CD20 Humanized Antibodies as Improved Lymphoma Therapeutics”, Cancer Res. 68:8384-92, 2008.Applicant
• Rossi et al. “Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting” Proc. Natl. Acad. Sci. Epub Apr. 24, 2006, vol. 103, No. 18, pp. 6841-6846.Applicant
• Rustandi et al., “The Ca2+-Dependent Interaction of S100B(ββ) with a Peptide Derived from p53”, Biochemistry 1998; 37: 1951-1960.Applicant
• Sabaawy et al., “Enhancement of 5-fluorouracil cytotoxicity on human colon cancer cells by retrovirus-mediated interferon-α gene transfer”, Int. J. Oncol. Jun. 1999; 14(6):1143-51.Applicant
• Salles et al., “Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study”, Blood 2008; 112:4824-4831.Applicant
• Santini et al., “Type I Interferon as a Powerful Adjuvant for Monocyte-derived Dendritic Cell Development and Activity In Vivo and in Hu-PBL-SCID Mice”, J. Exp. Med. 191(10):1777-1788 (2000).Applicant
• Scott et al., “Type II Regulatory Subunit Dimerization Determines the Subcellular Localization of the cAMP-dependent Protein Kinase”, J. Biol. Chem. 265:21561-66 (1990).Applicant
• Scott et al., “Cyclic nucleotide-dependent protein kinases”, Pharmacol. Ther. 1991;50(1):123-45.Applicant
• Seffernick et al., “Melamine Deaminase and Atrazine Chlorohydrolase: 98 Percent Identical but Functionally Different”, J. Bacteriol. 183(8):2405-2410 (2001).Applicant
• Sharkey et al., “Improved Therapeutic Results by Pretargeted Radioimmunotherapy of Non-Hodgkin's Lymphoma with a New Recombinant, Trivalent, Anti-CD20, Bispecific Antibody”, Cancer Res. 68:5282-90, 2008.Applicant
• Sharkey et al., “Metastatic Human Colonic Carcinoma: Molecular Imaging with Pretargeted SPECT and PET in a Mouse Model”, Radiology 246:497-507, 2008.Applicant
• Sidky et al., “Inhibition of Angiogenesis by Interferons: Effects on Tumor- and Lymphocyte-induced Vascular Responses”, Cancer Res. 47:5155-5161, Oct. 1, 1987.Applicant
• Stein et al., “Characterization of a New Humanized Anti-CD20 Monoclonal Antibody, IMMU-106, and Its Use in Combination with the Humanized Anti-CD22 Antibody, Epratuzumab, for the Therapy of Non-Hodgkin's Lymphoma”, Clin. Cancer Res. vol. 10, 2868-2878, Apr. 15, 2004.Applicant
• Stein et al., “Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab”, Blood 2006;108:2736-2744.Applicant
• Stokka et al., “Characterization of A-kinase-anchoring disruption using a solution-based assay”, Biochem. J. (2006) 400, 493-499.Applicant
• Stryer et al., “Levels of Structure in Protein Architecture”, Biochemistry, 3rd Ed., pp. 31-33, W.H. Freeman & Co., New York, 1988.Applicant
• Takaoka et al., “Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defence”, Nature Jul. 31, 2003;424(6948):516-23.Applicant
• Taylor, S., “cAMP-dependent Protein Kinase”, J. Biol. Chem. 1989;264(15):8443-8446.Applicant
• Walsh et al., “An Adenosine 3′, 5′-Monophosphate-dependant Protein Kinase from Rabbit Skeletal Muscle”, J. Biol. Chem. 243(13):3763-3774 (1968).Applicant
• Weck et al., “Comparison of the Antiviral Activities of Various Cloned Human Interferon-α Subtypes in Mammalian Cell Cultures”, J. Gen. Virol. (1981), 57, 233-237.Applicant
• Winkler et al., “Changing the Antigen Binding Specificity by Single Point Mutations of an Anti-p24 (HIV-1) Antibody”, J. Immunol. 165:4505-14, 2000.Applicant
• Witkowski et al., “Conversion of a β-Ketoacyl Synthase to a Malonyl Decarboxylase by Replacement of the Active-Site Cysteine with Glutamine”, Biochemistry 38(36):11643-50 (1999).Applicant
• Wong et al., “AKAP Signalling Complexes: Focal Points in Space and Time”, Nat. Rev. Mol. Cell Biol. 12:959-70 (2004).Applicant
• Zhu et al., “Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor”, Invest. New Drugs 17:195-212, 1999.Applicant
• Abbas et al., Cellular and Molecular Immunology, W.B. Saunders Comp. 1991, p. 43.Applicant
• Alto et al., “Bioinformatic design of A-kinase anchoring protein-in silico: a potent and selective peptide antagonist of type II protein kinase A anchoring” Proc. Natl. Acad. Sci USA Apr. 15, 2003; 100(8):4445-50.Applicant
• Backer et al., “Self-Assembled “Dock and Lock” System for Linking Payloads to Targeting Proteins” Bioconjugate Chem., 2006, 17(4):912-919.Applicant
• Baillie et al., “Compartmentalisation of phospodiesterases and protein kinase A: opposites attract”, FEBS Letters 2005; 579:3264-3270.Applicant
• Banky et al., “Dimerization/Docking Domain of the Type Iα Regulatory Subunit of cAMP-dependent Protein Kinase”, J. Biol. Chem. 273:35048-55, 1998.Applicant
• Basu et al., “Structure-Function Engineering of Interferon-β-1b for Improving Stability, Solubility, Potency, Immunogenicity, and Pharmacokinetic Properties by Site-Selective Mono-PEGylation”, Bioconjugate Chem. 2006; 17:618-630.Applicant
• Belardelli et al., “Interferon-alpha in tumor immunity and immunotherapy” Cytokine Growth Factor Rev. 13(2):119-134 (2002).Applicant
• Belardelli et al., “International Meeting on Cancer Vaccines: How Can We Enhance Efficacy of Therapeutic Vaccines?” Cancer Res. 64:6827-6830 (2004).Applicant
• Belardelli et al., “The neglected role of type I interferon in the T-cell response: implications for its clinical use” Immunol. Today 17(8):369-72 (1996).Applicant
• Biron et al., “Natural killer cells in antiviral defense: function and regulation by innate cytokines” Annu. Rev. Immunol. 17:189-220 (1999).Applicant
• Brunda et al., “Modulation of Murine Natural Killer Cell Activity in Vitro and in Vivo by Recombinant Human Interferons” Cancer Res. 44:597-601 (1984).Applicant
• Burns-Hamuro et al., “Distinct interaction modes of an AKAP bound to two regulatory subunit isoforms of protein kinase a revealed by amide hydrogen/deuterium exchange” Protein Science (2005), 14:2982-2992.Applicant
• Carr et al., “Interaction of the Regulatory Subunit (RII) of cAMP-dependent Protein Kinase with RII-anchoring Proteins Occurs through an Amphipathic Helix Binding Motif”, J. Biol. Chem. 266:14188-92 (1991).Applicant
• Carr et al., “Identification of Sperm-specific Proteins That Interact with A-kinase Anchoring Proteins in a Manner Similar to the Type II Regulatory Subunit of PKA” J. Biol. Chem. 276(20):17332-17338 (2001).Applicant
• Carrero et al., “Lymphocytes are detrimental during the early innate immune response against Listeria monocytogenes” J. Exp. Med. 203(4):933-940 (2006).Applicant
• Chang et al., “The Dock and Lock Method: A Novel Platform Technology for Building Multivalent, Multifunctional Structures of Defined Composition with Retained Bioactivity” Clin. Cancer Res. Sep. 15, 2007;13(18 Suppl), pp. 5586-5591.Applicant
• Chmura et al., “Antibodies with infinite affinity” Proc. Natl. Acad. Sci. USA 98(15):8480-8484 (2001).Applicant
• Colledge et al., “AKAPs: from structure to function”, Trends Cell Biol. 6:216-21 (1999).Applicant
• Corbin et al., “Regulation of Adenosine 3′,5′-Monophosphate-dependent Protein Kinase”, J. Biol. Chem. 248:1813-21 (1973).Applicant
• Dhalluin et al., “Structural and Biophysical Characterization of the 40 kDa PEG-Interferon-α2a and Its Individual Positional Isomers” Bioconjugate Chem. 2005;16:504-517.Applicant
• Dodart et al., “Immunotherapy for Alzheimer's Disease: will vaccination work?” Trends Mol. Med. 9(3):85-87 (2003).Applicant
• Doherty et al., “Site-Specific PEGylation of Engineered Cysteine Analogues of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor”, Bioconjugate Chem. 2005;16:1291-1298.Applicant
• Ferrantini et al., “IFN-α1 Gene Expression into a Metastatic Murine Adenocarcinoma (TS/A) Results in CD8+ T Cell-Mediated Tumor Rejection and Development of Antitumor Immunity” J. Immunol. 153:4604-15 (1994).Applicant
• Ferrantini et al., “Interferon-α and cancer: Mechanisms of action and new perspectives of clinical use” Biochimie 89: 884-893 (2007).Applicant
• Gillies et al., “High-level expression of chimeric antibodies using adapted cDNA variable region cassettes”, J. Immunol. Methods 125 (1989) 191-202.Applicant
• Glennie et al., “Mechanisms of killing by anti-CD20 monoclonal antibodies” Mol. Immunol. 44:3823-3837 (2007).Applicant
• Gold et al., “A Novel Bispecific, Trivalent Antibody Construct for Targeting Pancreatic Carcinoma”, Cancer Res. 68:4819-26, 2008.Applicant
• Gold et al., “Molecular Basis of AKAP Specificity for PKA Regulatory Subunits” Mol. Cell Nov. 3, 2006;24(3):383-95.Applicant
• Goldenberg et al., “Multifunctional Antibodies by the Dock-and-Lock Method for Improved Cancer Imaging and Therapy by Pretargeting”, J. Nucl. Med. 49:158-63, 2008.Applicant
• Goldenberg et al., “Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody” Blood 113:1062-70 (2009).Applicant
• Goodson et al., “Site-Directed PEGylation of Recombinant Interleukin-2 at its Glycosylation Site”, Nat. Biotechnology Apr. 1990;8(4):343-6.Applicant
• Grace et al., “Site of Pegylation and Polyethylene Glycol Molecule Size Attenuate Interferon-α Antiviral and Antiproliferative Activities through the JAK/STAT Signaling Pathway” J. Biol. Chem. 2005;280(8):6327-6336.Applicant
• Grimley et al., “Prolonged STAT1 Activation Related to the Growth Arrest of Malignant Lymphoma Cells by Interferon-α” Blood 91(8):3017-27 (1998).Applicant
• Gutterman et al., “Leukocyte Interferon-Induced Tumor Regression in Human Metastatic Breast Cancer, Multiple Myeloma, and Malignant Lymphoma” Ann. Intern. Med. 93(3):399-406 (1980).Applicant
• Gutterman et al., “Cytokine therapeutics: Lessons from interferon α” Proc. Natl. Acad. Sci. USA 91:1198-205 (1994).Applicant
• Harris et al., “Effect of pegylation on pharmaceuticals” Nat. Rev. Drug. Discov. 2:214-221 (2003).Applicant
• Hausken et al. “Mutational Analysis of the A-Kinase Anchoring Protein (AKAP)-binding Site on RII”, J. Biol. Chem. 271:29016-22 (1996).Applicant
• Hodneland et al., “Selective immobilization of proteins to self-assembled monolayers presenting active site-directed capture ligands”, Proc. Natl. Acd. Sci. USA 2002; 99:5048-5052.Applicant
• Huang et al., “Targeting IFN-α to B Cell Lymphoma by a Tumor-Specific Antibody Elicits Potent Antitumor Activities” J. Immunol. 179:6881-88 (2007).Applicant
• Hundsrucker et al., “High-affinity AKAP7δ-protein kinase a interaction yields novel protein kinase A-anchoring disruptor peptides” Biochem. J. (2006) 396, 297-306.Applicant
• Kimby et al., “Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma Group” Leuk. Lymphoma 49(1):102-112 (2008).Applicant
• Kinderman et al., “A Dynamic Mechanism for AKAP Binding to RII Isoforms of cAMP-Dependent Protein Kinase” Mol. Cell 24(3):397-408 (2006).Applicant
• Kinstler et al., “Characterization and Stability of N-terminally PEGylated rhG-CSF” Pharm. Res. 1996;13 (7):996-1002.Applicant
• Kramer et al., “Cell and virus sensitivity studies with recombinant human alpha interferons” J. Interferon. Res. 3 (4):425-35 (1983).Applicant
• Le Bon et al., “Type I Interferons Potently Enhance Humoral Immunity and Can Promote Isotype Switching by Stimulating Dendritic Cells In Vivo” Immunity 14:461-470 (2001).Applicant
• Lee et al., “Solid-Phase PEGylation of Recombinant Interferon α-2a for Site-Specific Modification: Process Performance, Characterization, and in Vitro Bioactivity” Bioconjugate Chem. 2007; 18:1728-34.Applicant
• Lohmann et al., “High-affinity binding of the regulatory subunit (RII) of cAMP-dependent protein kinase to microtubule-associated and other cellular proteins”, Proc. Natl. Acad. Sci. USA 81:6723-27 (1984).Applicant
• Luft et al., “Type I IFNs Enhance the Terminal Differentiation of Dendritic Cells” J. Immunol. 161:1947-1953 (1998).Applicant
• Mason, Anthony J., “Functional Analysis of the Cysteine Residues of Activin A”, Mol. Endocrinol. 8:325-32, 1994.Applicant
• Matarrese et al., “Type I Interferon Gene Transfer Sensitizes Melanoma Cells to Apoptosis via a Target Activity on Mitochondrial Function” Am. J. Pathol. 2002, 160(4):1507-1520.Applicant